Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

A Note from John Davidson, May 10

20-years-ago today was a good news-bad news kind of day. The bad news is the driving rain and incredibly high winds sweeping across the highway at a place called Wreck House on the west coast of Newfoundland all the way down into Port-aux-Basques, the departure point for Cape Breton. The good news is that we [...]

Capricor Recruiting Duchenne Patients for Phase 2 Trial of CAP-1002

Capricor Therapeutics’ Phase 2 clinical trial to evaluate the safety and effectiveness of CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD) has started recruiting participants. The HOPE-2 trial (NCT03406780) is planned to enroll up to 84 participants ages 10 or older with advanced stages of the disease who have been treated with standard therapies, including glucocorticoids. From […]


A Note from John Davidson, May 3

20-years-ago today was my 24th day on the road and I had reached Stephenville, Newfoundland after passing through Corner Brook on the more mountainous western side of Newfoundland. At one-time Stephenville was the largest United States airbase in the world, not located on American soil. But that was long ago. It was raining, dark and [...]

May is Defeat Duchenne Month

May 1 marks the beginning of Defeat Duchenne Month! During the month of May, families, businesses, and schools across Canada raise funds and awareness for Duchenne muscular dystrophy research. It’s easy to take part in Defeat Duchenne Month! Here are a few fundraising ideas: Gather a group of friends, family members, or co-workers and register for […]


Portrait of Duchenne: John and Jesse

John Davidson recently sat down with La Force DMD, a Duchenne muscular dystrophy advocacy organization based out of Quebec, as part of their “Portrait of Duchenne” series. They are releasing a series of videos featuring stories with those who face Duchenne muscular dystrophy every day – patients, parents, family members, and researchers. In his interview, […]


Capricor Initiates HOPE-2 Clinical Trial of Duchenne Drug

This morning, Capricor Therapeutics, Inc. announced that the HOPE-2 clinical trial has been initiated at UC Davis Medical Center in Sacramento, CA. The trial will evaluate the efficacy and safety of Capricor’s novel cellular treatment, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD), a devastating and life-threatening genetic disorder with few therapeutic […]


Ezutromid Shows Potential in DMD

Phase II study indicates modulating utrophin may reduce muscle inflammation LOS ANGELES — The investigative utrophin modulator ezutromid showed promise in treating Duchenne muscular dystrophy, according to a interim analysis of an open-label, phase II clinical trial. Ezutromid appeared to have significantly deceased inflammation in the calf muscle of Duchenne patients after 24 weeks, reported […]


Edasalonexent Could Reduce Functional Decline in Boys with DMD, MoveDMD Phase 2 Results Suggest

Results of the Phase 2 MoveDMD trial showed that Catabasis Pharmaceuticals’ candidate drug edasalonexent (CAT-1004) can reduce the rate of functional decline in boys ages 4–7 with Duchenne muscular dystrophy (DMD). The recent findings will be subject of a presentation titled, “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-kB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” […]


A Note from John Davidson, April 26

Editor’s Note: Just before I write my 20-years-ago today piece, I want to thank all those who attended the anniversary gala in London on April 10th. We premiered a new documentary at that time and we had greetings from Ottawa. I am providing the links for these pieces in the hope that you will enjoy [...]

Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.